Investigational Drug Details
| Drug ID: | D300 |
| Drug Name: | Resmetirom |
| Synonyms: | MGL-3196 |
| Type: | Chemical drug |
| DrugBank ID: | DB12914 |
| DrugBank Description: | MGL-3196 has been used in trials studying the treatment of Non-alcoholic steatohepatitis and Heterozygous Familial Hypercholesterolemia. |
| PubChem ID: | 15981237 |
| CasNo: | 920509-32-6 |
| Repositioning for NAFLD: | No |
| SMILES: | O=c1n(nc(c(=O)[nH]1)C#N)c1cc(Cl)c(c(c1)Cl)Oc1cc(C(C)C)c(=O)[nH]n1 |
| Structure: |
|
| InChiKey: | FDBYIYFVSAHJLY-UHFFFAOYSA-N |
| Molecular Weight: | 435.227 |
| DrugBank Targets: | -- |
| DrugBank MoA: | -- |
| DrugBank Pharmacology: | -- |
| DrugBank Indication: | -- |
| Targets: | THRB agonist |
| Therapeutic Category: | Anti-fibrosis |
| Clinical Trial Progress: | Phase 3 on-going (NCT04951219: Positive Topline Phase 3 MAESTRO-NAFLD-1 Data Demonstrate Resmetirom was Safe, Well-Tolerated and Provided Statistically Significant Improvements in Key Measures of Liver and Cardiovascular Health) |
| Latest Progress: | Advanced in clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0008 | NCT04951219 | Phase 3 | Recruiting | No Results Available | July 9, 2021 | August 19, 2021 | Details |
| L0009 | NCT04197479 | Phase 3 | Recruiting | No Results Available | December 16, 2019 | July 7, 2020 | Details |
| L0283 | NCT03900429 | Phase 3 | Recruiting | No Results Available | March 28, 2019 | July 7, 2021 | Details |
| L0465 | EUCTR2018-004012-22-FR | Phase 3 | Authorised | No Results Available | 03/06/2019 | 10 December 2019 | Details |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S03 | Anti-fibrosis | fibrosis | Angiotensin Receptor Blocker (ARB); CCR2/CCR5 antagonist; Thyroid receptor β agonist; PEGylated human FGF21 analogue; Monoclonal antibody to lysyl oxidase-like 2 (LOXL2); Galectin-3 inhibitor; FGF19 variant | Losartan; Cenicriviroc; VK-2809; MGL-3196; Pegbelfermin; Simtuzumab; GR-MD-02; NGM282 | Details |
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A00500 | 35060815 | Expert Opin Investig Drugs | Nonalcoholic steatohepatitis (NASH) cirrhosis: a snapshot of therapeutic agents in clinical development and the optimal design for clinical trials. | Details |
| A01057 | 34884910 | Int J Mol Sci | TG68, a Novel Thyroid Hormone Receptor-β Agonist for the Treatment of NAFLD. | Details |
| A01853 | 34588764 | Drug Des Devel Ther | Non-Alcoholic Steatohepatitis (NASH) - A Review of a Crowded Clinical Landscape, Driven by a Complex Disease. | Details |
| A03808 | 33860116 | Hepatol Commun | Effects of Resmetirom on Noninvasive Endpoints in a 36-Week Phase 2 Active Treatment Extension Study in Patients With NASH. | Details |
| A04346 | 33655500 | Br J Pharmacol | Activation of thyroid hormone receptor-β improved disease activity and metabolism independent of body weight in a mouse model of non-alcoholic steatohepatitis and fibrosis. | Details |
| A04749 | 33515800 | Ann Hepatol | Horizon scanning of therapeutic modalities for nonalcoholic steatohepatitis. | Details |
| A05080 | 33385317 | J Dig Dis | Efficacy and safety of drugs for nonalcoholic steatohepatitis. | Details |
| A05309 | 33306682 | PLoS One | Regulation of gene transcription by thyroid hormone receptor β agonists in clinical development for the treatment of non-alcoholic steatohepatitis (NASH). | Details |
| A05376 | 33278029 | Pharmacotherapy | Emerging therapies for the treatment of nonalcoholic steatohepatitis: A systematic review. | Details |
| A05793 | 33115209 | Diabetes Metab J | Nonalcoholic Fatty Liver Disease: A Drug Revolution Is Coming. | Details |
| A06825 | 32733906 | Front Med (Lausanne) | Selective Thyroid Hormone Receptor-Beta (TRβ) Agonists: New Perspectives for the Treatment of Metabolic and Neurodegenerative Disorders. | Details |
| A08327 | 32151660 | Metabolism | Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis. | Details |
| A08469 | 32098589 | Thyroid | Thyroid Hormone Analogues: An Update. | Details |
| A08581 | 32052857 | Hepatology | New Drugs for NASH and HIV Infection: Great Expectations for a Great Need. | Details |
| A09482 | 31727409 | Lancet | Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. | Details |
| A10083 | 31495973 | Hepatol Res | Phase 3 drug pipelines in the treatment of non-alcoholic steatohepatitis. | Details |
| A29268 | 34329774 | Clin Gastroenterol Hepatol | Hepatic Fat Reduction Due to Resmetirom in Patients With Nonalcoholic Steatohepatitis Is Associated With Improvement of Quality of Life. | Details |
| A43317 | 31985310 | Expert Opin Investig Drugs | Prof Jörn Schattenberg sheds light on key treatment and diagnostic approaches to nonalcoholic steatohepatitis (NASH). | Details |
| A43381 | 31868036 | Expert Opin Investig Drugs | Thyromimetics as emerging therapeutic agents for nonalcoholic steatohepatitis: rationale for the development of resmetirom (MGL-3196). | Details |
| A49230 | 35814516 | J Clin Exp Hepatol | Pharmacotherapeutic Impact on Nonalcoholic Steatohepatitis Histology: A Systematic Review and Network Meta-analysis. | Details |